Cancer Letters
Volume 243, Issue 2 , Pages 193-201 , 18 November 2006

mtDNA mutations in invasive cervix tumors: A retrospective analysis

  • Joan Allalunis-Turner

      Affiliations

    • Department of Oncology, University of Alberta, Edmonton, AB, Canada
    • Experimental Oncology, Cross Cancer Institute, Edmonton, AB, Canada
    • Corresponding Author InformationCorresponding author. Address: Cross Cancer Institute, 11560 University Avenue, Edmonton AB, Canada T6G 1Z2. Tel.: +1 780 432 8436; fax: +1 780 432 8892.
    • ,
  • Ivy Ma

      Affiliations

    • Experimental Oncology, Cross Cancer Institute, Edmonton, AB, Canada
    • ,
  • John Hanson

      Affiliations

    • Population Health and Information, Cross Cancer Institute, Edmonton, AB, Canada
    • ,
  • Robert G. Pearcey

      Affiliations

    • Department of Oncology, University of Alberta, Edmonton, AB, Canada
    • Radiation Oncology, Cross Cancer Institute, Edmonton, AB, Canada

Received 30 August 2005 ,Revised 24 November 2005 ,Accepted 27 November 2005.

References 

  1. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003;9:348–359
  2. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528–1536
  3. Perez CA, Grigsby PW, Nene SM, Camel HM, Galakatos A, Kao MS, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer. 1992;69:2796–2806
  4. Alvarez RD, Soong SJ, Kinney WK, Reid GC, Schray MF, Podratz KC, et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol. Oncol. 1989;35:130–135
  5. Obermair A, Wanner C, Bilgi S, Speiser P, Kaider A, Reinthaller A, et al. Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. Am. J. Obstet. Gynecol. 1998;178:314–319
  6. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br. J. Cancer. 2000;83:620–625
  7. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol. 1999;53:99–104
  8. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 1998;48:149–156
  9. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 1996;6:3–9
  10. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer. 2000;83:354–359
  11. Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenecker G, Reinthaller A. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol. Oncol. 1995;57:212–214
  12. Ebara T, Mitsuhashi N, Saito Y, Sakurai H, Hasegawa M, Takahashi M, et al. Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. Gynecol. Oncol. 1996;63:216–218
  13. Skomedal H, Kristensen GB, Lie AK, Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol. Oncol. 1999;73:223–228
  14. Shiohara S, Shiozawa T, Miyamoto T, Feng YZ, Kashima H, Kurai M, et al. Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch. 2005;446:626–633
  15. Sanseverino F, Torricelli M, Petraglia F, Giordano A. Role of the retinoblastoma family in gynecological cancer. Cancer Biol. Ther. 2003;2:636–641
  16. Graflund M, Sorbe B, Sigurdardottir S, Karlsson MG. Relation between HPV-DNA and expression of p53, bcl-2, p21WAF-1, MIB-1, HER-2/neu and DNA ploidy in early cervical carcinoma: correlation with clinical outcome. Oncol. Rep. 2004;12:169–176
  17. Dellas A, Schultheiss E, Leivas MR, Moch H, Torhorst J. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. Anticancer Res. 1998;18:3991–3998
  18. Kirches E, Krause G, Warich-Kirches M, Weis S, Schneider T, Meyer-Puttlitz B, et al. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples. Int. J. Cancer. 2001;93:534–538
  19. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 2000;287:2017–2019
  20. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet. 1998;20:291–293
  21. Parrella P, Seripa D, Matera MG, Rabitti C, Rinaldi M, Mazzarelli P, et al. Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett. 2003;190:73–77
  22. Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283:1482–1488
  23. van den Heuvel L, Smeitink J. The oxidative phosphorylation (OXPHOS) system: nuclear genes and human genetic diseases. Bioessays. 2001;23:518–525
  24. Schon EA. Mitochondrial genetics and disease. Trends Biochem. Sci. 2000;25:555–560
  25. Chomyn A. Mitochondrial genetic control of assembly and function of complex I in mammalian cells. J. Bioenerg. Biomembr. 2001;33:251–257
  26. Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, et al. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res. 2001;61:7623–7626
  27. Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, et al. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res. 2001;61:7015–7019
  28. Yeh JJ, Lunetta KL, van Orsouw NJ, Moore FDJ, Mutter GL, Vijg J, et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene. 2000;19:2060–2066
  29. Coller HA, Khrapko K, Bodyak ND, Nekhaeva E, Herrero-Jimenez P, Thilly WG. High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nat. Genet. 2001;28:147–150
  30. Allalunis-Turner MJ, Pearcey RG, Barron GM, Buryn DA, Babiak JC, Honore LH. Inherent radiosensitivity testing of tumor biopsies obtained from patients with carcinoma of the cervix or endometrium. Radiother. Oncol. 1991;22:201–205
  31. Brandon MC, Lott MT, Nguyen KC, Spolim S, Navathe SB, Baldi P, et al. MITOMAP: a human mitochondrial genome database—2004 update. Nucleic Acids Res. 2005;33(Database Issue):D611–D613
  32. Taylor RW, Taylor GA, Durham SE, Turnbull DM. The determination of complete human mitochondrial DNA sequences in single cells: implications for the study of somatic mitochondrial DNA point mutations. Nucleic Acids Res. 2001;29:E74
  33. Brown MD, Voljavec AS, Lott MT, Torroni A, Yang CC, Wallace DC. Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics. 1992;130:163–173
  34. Howell N, Kubacka I, Halvorson S, Howell B, McCullough DA, Mackey D. Phylogenetic analysis of the mitochondrial genomes from Leber hereditary optic neuropathy pedigrees. Genetics. 1995;140:285–302
  35. Kosel S, Grasbon-Frodl EM, Mautsch U, Egensperger R, von Eitzen U, Frishman D, et al. Novel mutations of mitochondrial complex I in pathologically proven Parkinson disease. Neurogenetics. 1998;1:197–204
  36. Tan DJ, Bai RK, Wong LJ. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 2002;62:972–976
  37. Matsuyama W, Nakagawa M, Wakimoto J, Hirotsu Y, Kawabata M, Osame M. Mitochondrial DNA mutation correlates with stage progression and prognosis in non-small cell lung cancer. Hum. Mutat. 2003;21:441–443
  38. Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia. 2003;17:1437–1447
  39. Zhu W, Qin W, Bradley P, Wessel A, Puckett CL, Sauter ER. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis. 2005;26:145–152
  40. Liu VW, Shi HH, Cheung AN, Chiu PM, Leung TW, Nagley P, et al. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 2001;61:5998–6001
  41. Chen JZ, Gokden N, Greene GF, Green B, Kadlubar FF. Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hyper-mutagenesis. Carcinogenesis. 2003;24:1481–1487
  42. Knight JC. Regulatory polymorphisms underlying complex disease traits. J. Mol. Med. 2005;83:97–109
  43. Chomyn A. Mitochondrial genetic control of assembly and function of complex I in mammalian cells. J. Bioenerg. Biomembr. 2001;33:251–257
  44. Bai Y, Hu P, Park JS, Deng JH, Song X, Chomyn A, et al. Genetic and functional analysis of mitochondrial DNA-encoded complex I genes. Ann. NY Acad. Sci. 2004;1011:272–283
  45. Grossman LI, Shoubridge EA. Mitochondrial genetics and human disease. Bioessays. 1996;18:983–991
  46. Singh KK. Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann. NY Acad. Sci. 2004;1019:260–264
  47. Dufour E, Larsson NG. Understanding aging: revealing order out of chaos. Biochim. Biophys. Acta. 2004;1658:122–132
  48. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer Suppl. 1978;37:302–306
  49. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528–1536
  50. Wilailak S, Rochanawutanon M, Srisupundit S, Aumkhyan A, Pattanapanyasat K. Flow cytometric analysis of DNA ploidy and S-phase fraction of Stage IIIB cervical carcinoma. Eur. J. Gynaecol. Oncol. 2004;25:428–430
  51. Gasinska A, Urbanski K, Jakubowicz J, Klimek M, Biesaga B, Wilson GD. Tumour cell kinetics as a prognostic factor in squamous cell carcinoma of the cervix treated with radiotherapy. Radiother. Oncol. 1999;50:77–84
  52. Kristensen GB, Kaern J, Abeler VM, Hagmar B, Trope CG, Pettersen EO. No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients. Gynecol. Oncol. 1995;57:79–85
  53. Lewis PD, Parry JM. In silico p53 mutation hotspots in lung cancer. Carcinogenesis. 2004;25:1099–1107

PII: S0304-3835(05)01044-X

doi: 10.1016/j.canlet.2005.11.035

Cancer Letters
Volume 243, Issue 2 , Pages 193-201 , 18 November 2006

Article Tools

* Image Usage & Resolution